S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

$17.54
-0.97 (-5.24%)
(As of 04/12/2024 08:52 PM ET)
Today's Range
$17.12
$18.54
50-Day Range
$13.31
$21.47
52-Week Range
$4.29
$21.88
Volume
875,200 shs
Average Volume
1.50 million shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

MacroGenics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
3.1% Downside
$17.00 Price Target
Short Interest
Bearish
11.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.49mentions of MacroGenics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.44 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.70) to ($1.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

362nd out of 928 stocks

Pharmaceutical Preparations Industry

155th out of 426 stocks

MGNX stock logo

About MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock Price History

MGNX Stock News Headlines

Bitcoin’s All Time High Is Just the Beginning
Bitcoin has officially hit a new all-time high. But if you think you’re too late… Think again.
MacroGenics (NASDAQ:MGNX) Upgraded to "Buy" by TD Cowen
MacroGenics (NASDAQ:MGNX) Trading Up 4.7%
Bitcoin’s All Time High Is Just the Beginning
Bitcoin has officially hit a new all-time high. But if you think you’re too late… Think again.
The Latest Analyst Ratings For Macrogenics
MGNX Apr 2024 10.000 put
MGNX Dec 2024 17.500 put
MGNX Mar 2024 22.500 put
MacroGenics price target raised by $12 at Citi, here's why
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/14/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MGNX
Employees
339
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$24.00
Low Stock Price Target
$12.00
Potential Upside/Downside
-3.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-9,060,000.00
Pretax Margin
-15.42%

Debt

Sales & Book Value

Annual Sales
$57.19 million
Book Value
$2.46 per share

Miscellaneous

Free Float
56,305,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
2.09

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Scott Koenig M.D. (Age 72)
    Ph.D., President, CEO & Director
    Comp: $1.06M
  • Mr. James KarrelsMr. James Karrels (Age 57)
    Senior VP, CFO & Corporate Secretary
    Comp: $626.83k
  • Mr. Eric Blasius Risser (Age 51)
    Chief Operating Officer
    Comp: $651.36k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 57)
    Senior Vice President of Technical Operations
    Comp: $550.97k
  • Dr. Ezio Bonvini (Age 70)
    Senior VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Mr. Jeffrey Stuart Peters (Age 53)
    Senior VP, General Counsel & Corporate Compliance Officer
  • Dr. Stephen L. Eck M.D. (Age 69)
    Ph.D., Senior VP of Clinical Development & Chief Medical Officer
    Comp: $577.62k
  • Ms. Lynn Cilinski (Age 66)
    VP, Controller & Treasurer

MGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price target for 2024?

8 brokerages have issued 1 year target prices for MacroGenics' shares. Their MGNX share price targets range from $12.00 to $24.00. On average, they expect the company's stock price to reach $17.00 in the next year. This suggests that the stock has a possible downside of 3.1%.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2024?

MacroGenics' stock was trading at $9.62 at the start of the year. Since then, MGNX shares have increased by 82.3% and is now trading at $17.54.
View the best growth stocks for 2024 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) announced its earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.49. The biopharmaceutical company earned $10.72 million during the quarter, compared to analysts' expectations of $25.70 million. MacroGenics had a negative trailing twelve-month return on equity of 88.49% and a negative net margin of 15.42%. During the same quarter in the prior year, the firm earned $0.21 earnings per share.

What ETFs hold MacroGenics' stock?

ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).iShares Micro-Cap ETF (IWC).

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.09%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGNX) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners